Can glucagon-like peptide‑1 receptor agonists affect the efficacy of the oral iron supplement Haley Fe 1‑20?

GLP-1 Receptor Agonists Can Reduce Iron Absorption and May Decrease Efficacy of Haley Fe 1-20

Yes, GLP-1 receptor agonists can potentially affect the efficacy of Haley Fe 1-20 (an oral contraceptive with iron supplementation) through multiple mechanisms that impair iron absorption, though no direct drug interaction is documented in the FDA label.

Mechanism of Reduced Iron Absorption

GLP-1 receptor agonists significantly delay gastric emptying by inhibiting gastric peristalsis and increasing pyloric tone through vagal nerve-mediated pathways 1. This creates several conditions that impair oral iron absorption:

• Delayed gastric emptying reduces the time iron spends in the duodenum and proximal jejunum, where iron absorption is optimal
• Reduced gastric acid secretion 1 decreases the conversion of ferric iron (Fe³⁺) to the more absorbable ferrous form (Fe²⁺)
• Decreased small intestinal motility limits iron contact with absorptive surfaces

Clinical Evidence of Iron Deficiency with GLP-1 Agonists

Recent observational data demonstrates that GLP-1 receptor agonist users develop iron depletion, with ferritin levels 26-30% lower compared to patients on SGLT2 inhibitors 2. Iron deficiency is emerging as a recognized adverse effect, with mechanisms including:

• Inadequate dietary iron intake due to appetite suppression
• Impaired intestinal iron absorption from delayed gastric emptying
• Reduced gastric acid secretion affecting iron solubility 3

More than 60% of GLP-1 agonist users consume below estimated requirements for iron 2.

Impact on Haley Fe 1-20 Components

Iron Component (Ferrous Fumarate)

The 7 brown tablets containing ferrous fumarate in Haley Fe 1-20 are designed to prevent iron deficiency during menstruation 4. GLP-1 agonists may reduce absorption of this supplemental iron, potentially leading to:

• Progressive iron depletion over time
• Increased risk of iron deficiency anemia
• Reduced therapeutic benefit of the iron supplementation

Contraceptive Component

The FDA label for Haley Fe 1-20 does not list GLP-1 agonists as affecting contraceptive efficacy 4. However, the delayed gastric emptying caused by GLP-1 agonists could theoretically affect absorption of norethindrone acetate and ethinyl estradiol, though no clinical evidence currently supports reduced contraceptive efficacy.

Practical Management Strategy

For patients on both GLP-1 agonists and Haley Fe 1-20:

1. Monitor iron status at baseline, 6 months, and 12 months with:

   • Serum ferritin (most sensitive early marker)
   • Complete blood count
   • Transferrin saturation if ferritin is low

2. Optimize iron absorption timing:

   • Take iron tablets on an empty stomach when possible
   • Separate from GLP-1 agonist injection by several hours
   • Consider taking with vitamin C (ascorbic acid) to enhance absorption

3. Consider higher-dose iron supplementation if ferritin trends downward, as the 7 tablets per month in Haley Fe 1-20 may be insufficient

4. Evaluate for additional iron supplementation if ferritin falls below 30 ng/mL or if anemia develops

5. Assess dietary iron intake and counsel on iron-rich foods, as GLP-1-induced appetite suppression reduces overall nutrient intake 2, 3

Important Caveats

• The gastric emptying effects of GLP-1 agonists show tachyphylaxis over time 1, with more pronounced effects in the first weeks of treatment
• Short-acting GLP-1 agonists (exenatide, liraglutide) may have more persistent gastric emptying effects than long-acting formulations (semaglutide) 1
• No established guidelines currently exist for managing iron deficiency specifically in GLP-1 agonist users 3

The contraceptive efficacy of Haley Fe 1-20 should remain intact, but the iron supplementation component may be compromised, requiring proactive monitoring and potential dose adjustment.